Venlafaxine-associated serotonin syndrome causing severe rhabdomyolysis and acute renal failure in a patient with idiopathic parkinson disease

Journal of Clinical Psychopharmacology

Volumn 30, Issue 5, 2010, Pages 620-622

  Rajapakse, Senaka ^a   Abeynaike, Lakshan ^b   Wickramarathne, Thanushi ^b  

^a UNIVERSITY OF COLOMBO   (Sri Lanka)

^b University Medical Unit   (Sri Lanka)

Author keywords

neuroleptic malignant syndrome; rhabdomyolysis; serotonin syndrome; venlafaxine

Indexed keywords

AMANTADINE; CARBIDOPA; LEVODOPA; ROPINIROLE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRIHEXYPHENIDYL; VENLAFAXINE;

ACUTE KIDNEY FAILURE; ADULT; AGITATION; ARTICLE; CASE REPORT; CONFUSION; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEPRESSION; DIAPHORESIS; DIFFERENTIAL DIAGNOSIS; DRUG OVERDOSE; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HYPERKINESIA; IDIOPATHIC DISEASE; MALE; MYOGLOBINURIA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RHABDOMYOLYSIS; SEROTONIN SYNDROME; SIDE EFFECT; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ADULT; CYCLOHEXANOLS; HUMANS; MALE; PARKINSON DISEASE; RHABDOMYOLYSIS; SEROTONIN SYNDROME;

EID: 77957278304     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181ee2ae7     Document Type: Article

References (27)

1. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16: 54SY59S; discussion 9SY61S.
2. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355: 911-918.
3. Oliver JJ, Kelly C, Jarvie D, et al. Venlafaxine poisoning complicated by a late rise in creatine kinase: two case reports. Hum Exp Toxicol. 2002;21: 463-466. (Pubitemid 35256457)
4. Pascale P, Oddo M, Pacher P, et al. Severe rhabdomyolysis following venlafaxine overdose. Ther Drug Monit. 2005;27: 562-564. (Pubitemid 41437631)
5. Wilson AD, Howell C, Waring WS. Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series. J Toxicol Sci. 2007;32: 97-101. (Pubitemid 46334074)
6. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;96: 369-374. (Pubitemid 36592709)
7. Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf. 2008;7: 587-596.
8. Lu TC, Chu PL, Wu CS, et al. Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder. J Formos Med Assoc. 2006;105: 90-93. (Pubitemid 43125357)
9. Nimmagadda SR, Ryan DH, Atkin SL. Neuroleptic malignant syndrome after venlafaxine. Lancet. 2000;355: 289-290.
10. Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med. 1989;149: 1927-1931. (Pubitemid 19232210)
11. Sakkas P, Davis JM, Janicak PG, et al. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27: 381-384.
12. Sandyk R. L-dopa induced Bserotonin syndrome[ in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol. 1986;6: 194-195.
13. Kline SS, Mauro LS, Scala-Barnett DM, et al. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm. 1989;8: 510-514. (Pubitemid 19198272)
14. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry. 1991;159: 709-712.
15. Caroff S, S.C. M, Francis A, et al. Catatonia, from Psychopathology to Neurobiology. Arlington, VA: American Psychiatric Publishing; 2004.
16. Fink M, Taylor MA. Catatonia. Cambridge, UK: Cambridge University Press; 2003.
17. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13: 100-109.
18. Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med. 1999;33: 457-459. (Pubitemid 29157574)
19. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352: 1112-1120.
20. Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96: 635-642. (Pubitemid 37063272)
21. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148: 705-713.
22. Fink M. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry. 1996;29: 159-161. (Pubitemid 26247567)
23. Otani K, Horiuchi M, Kondo T, et al. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry. 1991;158: 850-853.
24. Mihara K, Kondo T, Suzuki A, et al. Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet. 2003;117: 57-60. (Pubitemid 37059361)
25. Maj J, Rogoz Z. Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems. J Neural Transm. 1999;106: 197-211. (Pubitemid 29137516)
26. Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother. 2008;42: 1290-1297.
27. Davis JM, Janicak PG, Sakkas P, et al. Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther. 1991;7: 111-120.